<table id="table17" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 17: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs<sup>a</sup>
</caption>
<col span="1" width="17%"></col>
<col span="1" width="18%"></col>
<col span="1" width="19%"></col>
<col span="1" width="15%"></col>
<col span="1" width="15%"></col>
<col span="1" width="16%"></col>
<tbody>
<tr>
<th colspan="1">
<content stylecode="bold">Coadministered Drug</content>
</th>
<th colspan="1">
<content stylecode="bold">Coadministered Drug<br/>Dose/Schedule</content>
</th>
<th colspan="1">
<content stylecode="bold">REYATAZ<br/>Dose/Schedule</content>
</th>
<th colspan="3">
<content stylecode="bold">Ratio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without Coadministered Drug;<br/>No Effect = 1.00</content>
</th>
</tr>
<tr>
<th colspan="1">
<content stylecode="bold">C<sub>max</sub>
</content>
</th>
<th colspan="1">
<content stylecode="bold">AUC</content>
</th>
<th colspan="1">
<content stylecode="bold">C<sub>min</sub>
</content>
</th>
</tr>
<tr>
<td>atenolol</td>
<td>50 mg QD, d 7−11 (n=19) and d 19−23</td>
<td>400 mg QD, d 1−11 (n=19)</td>
<td>1.00<br/>(0.89, 1.12)</td>
<td>0.93<br/>(0.85, 1.01)</td>
<td>0.74<br/>(0.65, 0.86)</td>
</tr>
<tr>
<td>boceprevir</td>
<td>800 mg TID,<br/>d 1−6, 25−31</td>
<td>300 mg QD/ritonavir<br/>100 mg QD, d 10−31 </td>
<td>atazanavir: 0.75<br/>(0.64−0.88)</td>
<td>atazanavir: 0.65<br/>(0.55−0.78) </td>
<td>atazanavir: 0.51<br/>(0.44−0.61)</td>
</tr>
<tr>
<td> </td>
<td></td>
<td></td>
<td>ritonavir: 0.73<br/>(0.64−0.83)</td>
<td>ritonavir: 0.64<br/>(0.58−0.72)</td>
<td>ritonavir: 0.55<br/>(0.45−0.67)</td>
</tr>
<tr>
<td>clarithromycin</td>
<td>500 mg BID, d 7−10 (n=29) and d 18−21</td>
<td>400 mg QD, d 1−10 (n=29)</td>
<td>1.06<br/>(0.93, 1.20)</td>
<td>1.28<br/>(1.16, 1.43)</td>
<td>1.91<br/>(1.66, 2.21)</td>
</tr>
<tr>
<td>didanosine (ddI) (buffered tablets) plus stavudine (d4T)<sup>b</sup>
</td>
<td>ddI: 200 mg x 1 dose,<br/>d4T: 40 mg x 1 dose (n=31)</td>
<td>400 mg x 1 dose simultaneously with ddI and d4T (n=31)</td>
<td>0.11<br/>(0.06, 0.18)</td>
<td>0.13<br/>(0.08, 0.21)</td>
<td>0.16<br/>(0.10, 0.27)</td>
</tr>
<tr>
<td> </td>
<td>ddI: 200 mg x 1 dose,<br/>d4T: 40 mg x 1 dose (n=32)</td>
<td>400 mg x 1 dose 1 h after ddI + d4T (n=32)</td>
<td>1.12<br/>(0.67, 1.18)</td>
<td>1.03<br/>(0.64, 1.67)</td>
<td>1.03<br/>(0.61, 1.73)</td>
</tr>
<tr>
<td>ddI (enteric-coated [EC] capsules)<sup>c</sup>
</td>
<td>400 mg d 8 (fed) (n=34) 400 mg d 19 (fed) (n=31)</td>
<td>400 mg QD, d 2−8 (n=34) 300 mg/ritonavir 100 mg QD, d 9−19 (n=31)</td>
<td>1.03<br/>(0.93, 1.14)<br/>1.04<br/>(1.01, 1.07)</td>
<td>0.99<br/>(0.91, 1.08)<br/>1.00<br/>(0.96, 1.03)</td>
<td>0.98<br/>(0.89, 1.08)<br/>0.87<br/>(0.82, 0.92)</td>
</tr>
<tr>
<td>diltiazem</td>
<td>180 mg QD, d 7−11 (n=30) and d 19−23</td>
<td>400 mg QD, d 1−11 (n=30)</td>
<td>1.04<br/>(0.96, 1.11)</td>
<td>1.00<br/>(0.95, 1.05)</td>
<td>0.98<br/>(0.90, 1.07)</td>
</tr>
<tr>
<td>efavirenz</td>
<td>600 mg QD, d 7−20 (n=27)</td>
<td>400 mg QD, d 1−20 (n=27)</td>
<td>0.41<br/>(0.33, 0.51)</td>
<td>0.26<br/>(0.22, 0.32)</td>
<td>0.07<br/>(0.05, 0.10)</td>
</tr>
<tr>
<td> </td>
<td>600 mg QD, d 7−20 (n=13)</td>
<td>400 mg QD, d 1−6 (n=23) then 300 mg/ritonavir 100 mg QD, 2 h before efavirenz, d 7−20 (n=13)</td>
<td>1.14<br/>(0.83, 1.58)</td>
<td>1.39<br/>(1.02, 1.88)</td>
<td>1.48<br/>(1.24, 1.76)</td>
</tr>
<tr>
<td> </td>
<td>600 mg QD, d 11–24 (pm) (n=14)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 1–10 (pm) (n=22), then 400 mg QD/ritonavir 100 mg QD, d 11–24 (pm), (simultaneous with efavirenz) (n=14)</td>
<td>1.17<br/>(1.08, 1.27)</td>
<td>1.00<br/>(0.91, 1.10)</td>
<td>0.58<br/>(0.49, 0.69)</td>
</tr>
<tr>
<td>famotidine</td>
<td>40 mg BID, d 7−12 (n=15)</td>
<td>400 mg QD, d 1−6 (n=45), d 7−12 (simultaneous administration) (n=15)</td>
<td>0.53<br/>(0.34, 0.82)</td>
<td>0.59<br/>(0.40, 0.87) </td>
<td>0.58<br/>(0.37, 0.89)</td>
</tr>
<tr>
<td> </td>
<td>40 mg BID, d 7−12 (n=14)</td>
<td>400 mg QD (pm), d 1−6 (n=14), d 7−12 (10 h after, 2 h before famotidine) (n=14)</td>
<td>1.08<br/>(0.82, 1.41)</td>
<td>0.95<br/>(0.74, 1.21)</td>
<td>0.79<br/>(0.60, 1.04)</td>
</tr>
<tr>
<td> </td>
<td>40 mg BID, d 11−20 (n=14)<sup>d</sup>
</td>
<td>300 mg QD/ritonavir 100 mg QD, d 1−10 (n=46), d 11−20<sup>d</sup> (simultaneous administration) (n=14)</td>
<td>0.86<br/>(0.79, 0.94)</td>
<td>0.82<br/>(0.75, 0.89)</td>
<td>0.72<br/>(0.64, 0.81)</td>
</tr>
<tr>
<td> </td>
<td>20 mg BID, d 11−17 (n=18)</td>
<td>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 11−17 (am) (simultaneous administration with am famotidine) (n=18)<sup>e,f</sup>
</td>
<td>0.91<br/>(0.84, 0.99)</td>
<td>0.90<br/>(0.82, 0.98)</td>
<td>0.81<br/>(0.69, 0.94)</td>
</tr>
<tr>
<td> </td>
<td>40 mg QD (pm),<br/>d 18−24 (n=20)</td>
<td>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (12 h after pm famotidine) (n=20)<sup>f</sup>
</td>
<td>0.89<br/>(0.81, 0.97)</td>
<td>0.88<br/>(0.80, 0.96)</td>
<td>0.77<br/>(0.63, 0.93)</td>
</tr>
<tr>
<td> </td>
<td>40 mg BID, d 18−24 (n=18)</td>
<td>300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, d 1−10 (am) (n=39), d 18−24 (am) (10 h after pm famotidine and 2 h before am famotidine) (n=18)<sup>f</sup>
</td>
<td>0.74<br/>(0.66, 0.84)</td>
<td>0.79<br/>(0.70, 0.88)</td>
<td>0.72<br/>(0.63, 0.83)</td>
</tr>
<tr>
<td> </td>
<td>40 mg BID, d 11−20 (n=15)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 1−10 (am) (n=46), then 400 mg QD/ritonavir 100 mg QD, d 11−20 (am) (n=15)</td>
<td>1.02<br/>(0.87, 1.18)</td>
<td>1.03<br/>(0.86, 1.22)</td>
<td>0.86<br/>(0.68, 1.08)</td>
</tr>
<tr>
<td>fluconazole</td>
<td>200 mg QD, d 11−20 (n=29)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 1−10 (n=19), d 11−20 (n=29)</td>
<td>1.03<br/>(0.95, 1.11)</td>
<td>1.04<br/>(0.95, 1.13)</td>
<td>0.98<br/>(0.85, 1.13)</td>
</tr>
<tr>
<td>ketoconazole</td>
<td>200 mg QD, d 7−13 (n=14)</td>
<td>400 mg QD, d 1−13 (n=14)</td>
<td>0.99<br/>(0.77, 1.28)</td>
<td>1.10<br/>(0.89, 1.37)</td>
<td>1.03<br/>(0.53, 2.01)</td>
</tr>
<tr>
<td>nevirapine<sup>g,h</sup>
</td>
<td>200 mg BID, d 1–23 (n=23)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 4–13, then 400 mg QD/ritonavir 100 mg QD, d 14–23 (n=23)<sup>i</sup>
</td>
<td>0.72<br/>(0.60, 0.86)<br/>1.02<br/>(0.85, 1.24)</td>
<td>0.58<br/>(0.48, 0.71)<br/>0.81<br/>(0.65, 1.02)</td>
<td>0.28<br/>(0.20, 0.40)<br/>0.41<br/>(0.27, 0.60)</td>
</tr>
<tr>
<td>omeprazole</td>
<td>40 mg QD, d 7−12 (n=16)<sup>j</sup>
</td>
<td>400 mg QD, d 1−6 (n=48), d 7−12 (n=16)</td>
<td>0.04<br/>(0.04, 0.05)</td>
<td>0.06<br/>(0.05, 0.07)</td>
<td>0.05<br/>(0.03, 0.07)</td>
</tr>
<tr>
<td> </td>
<td>40 mg QD, d 11−20 (n=15)<sup>j</sup>
</td>
<td>300 mg QD/ritonavir 100 mg QD, d 1−20 (n=15)</td>
<td>0.28<br/>(0.24, 0.32)</td>
<td>0.24<br/>(0.21, 0.27)</td>
<td>0.22<br/>(0.19, 0.26)</td>
</tr>
<tr>
<td> </td>
<td>20 mg QD, d 17−23 (am) (n=13)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 7−16 (pm) (n=27), d 17−23 (pm) (n=13)<sup>k,l</sup>
</td>
<td>0.61<br/>(0.46, 0.81)</td>
<td>0.58<br/>(0.44, 0.75)</td>
<td>0.54<br/>(0.41, 0.71)</td>
</tr>
<tr>
<td> </td>
<td>20 mg QD, d 17−23 (am) (n=14)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 7−16 (am) (n=27), then 400 mg QD/ritonavir 100 mg QD, d 17−23 (am) (n=14)<sup>m,n</sup>
</td>
<td>0.69<br/>(0.58, 0.83)</td>
<td>0.70<br/>(0.57, 0.86)</td>
<td>0.69<br/>(0.54, 0.88)</td>
</tr>
<tr>
<td>pitavastatin</td>
<td>4 mg QD<br/>for 5 days</td>
<td>300 mg QD<br/>for 5 days</td>
<td>1.13<br/>(0.96, 1.32)</td>
<td>1.06<br/>(0.90, 1.26)</td>
<td>NA</td>
</tr>
<tr>
<td>rifabutin</td>
<td>150 mg QD, d 15−28 (n=7)</td>
<td>400 mg QD, d 1−28 (n=7)</td>
<td>1.34<br/>(1.14, 1.59)</td>
<td>1.15<br/>(0.98, 1.34)</td>
<td>1.13<br/>(0.68, 1.87)</td>
</tr>
<tr>
<td>rifampin</td>
<td>600 mg QD, d 17−26 (n=16)</td>
<td>300 mg QD/ritonavir 100 mg QD, d 7−16 (n=48), d 17−26 (n=16)</td>
<td>0.47<br/>(0.41, 0.53)</td>
<td>0.28<br/>(0.25, 0.32)</td>
<td>0.02<br/>(0.02, 0.03)</td>
</tr>
<tr>
<td>ritonavir<sup>o</sup>
</td>
<td>100 mg QD, d 11−20 (n=28)</td>
<td>300 mg QD, d 1−20 (n=28)</td>
<td>1.86<br/>(1.69, 2.05)</td>
<td>3.38<br/>(3.13, 3.63)</td>
<td>11.89<br/>(10.23, 13.82)</td>
</tr>
<tr>
<td>telaprevir</td>
<td>750 mg q8h<br/>for 10 days<br/>(n=7)</td>
<td>300 mg QD/ritonavir<br/>100 mg QD for 20 days<br/>(n=7)</td>
<td>0.85<br/>(0.73, 0.98)</td>
<td>1.17<br/>(0.97, 1.43)</td>
<td>1.85<br/>(1.40, 2.44)</td>
</tr>
<tr>
<td>tenofovir<sup>p</sup>
</td>
<td>300 mg QD, d 9−16 (n=34)</td>
<td>400 mg QD, d 2−16 (n=34)</td>
<td>0.79<br/>(0.73, 0.86)</td>
<td>0.75<br/>(0.70, 0.81)</td>
<td>0.60<br/>(0.52, 0.68)</td>
</tr>
<tr>
<td> </td>
<td>300 mg QD, d 15−42 (n=10)</td>
<td>300 mg/ritonavir 100 mg QD, d 1−42 (n=10)</td>
<td>0.72<sup>q</sup>
<br/>(0.50, 1.05)</td>
<td>0.75<sup>q </sup>
<br/>(0.58, 0.97)</td>
<td>0.77<sup>q</sup>
<br/>(0.54, 1.10)</td>
</tr>
<tr>
<td>voriconazole<br/>(Subjects with at least one functional CYP2C19 allele)</td>
<td>200 mg BID, d 2−3, 22−30;<br/>400 mg BID, d 1, 21<br/>(n=20)</td>
<td>300 mg/ritonavir 100 mg QD, d 11−30<br/>(n=20)</td>
<td>0.87<br/>(0.80, 0.96)</td>
<td>0.88<br/>(0.82, 0.95) </td>
<td>0.80<br/>(0.72, 0.90)</td>
</tr>
<tr>
<td>voriconazole<br/>(Subjects without a functional CYP2C19 allele)</td>
<td>50 mg BID, d 2−3, 22−30;<br/>100 mg BID, d 1, 21<br/>(n=8)</td>
<td>300 mg/ritonavir 100 mg QD, d 11−30<br/>(n=8)</td>
<td>0.81<br/>(0.66, 1.00)</td>
<td>0.80<br/>(0.65, 0.97) </td>
<td>0.69<br/>(0.54, 0.87)</td>
</tr>
</tbody>
</table>